SG11201700958YA - Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole - Google Patents
Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazoleInfo
- Publication number
- SG11201700958YA SG11201700958YA SG11201700958YA SG11201700958YA SG11201700958YA SG 11201700958Y A SG11201700958Y A SG 11201700958YA SG 11201700958Y A SG11201700958Y A SG 11201700958YA SG 11201700958Y A SG11201700958Y A SG 11201700958YA SG 11201700958Y A SG11201700958Y A SG 11201700958YA
- Authority
- SG
- Singapore
- Prior art keywords
- benzoxazole
- dichlorophenyl
- carboxy
- crystalline solid
- solid forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047614P | 2014-09-08 | 2014-09-08 | |
| US201562203953P | 2015-08-12 | 2015-08-12 | |
| PCT/IB2015/056597 WO2016038500A1 (en) | 2014-09-08 | 2015-08-31 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700958YA true SG11201700958YA (en) | 2017-03-30 |
Family
ID=54199901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700958YA SG11201700958YA (en) | 2014-09-08 | 2015-08-31 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9770441B1 (en) |
| EP (3) | EP3191461B1 (en) |
| JP (4) | JP2016065042A (en) |
| KR (1) | KR102004059B1 (en) |
| CN (2) | CN115368313A (en) |
| AU (1) | AU2015313875B2 (en) |
| BR (1) | BR112017003421B1 (en) |
| CA (1) | CA2903194A1 (en) |
| CY (1) | CY1124843T1 (en) |
| DK (1) | DK3977993T3 (en) |
| ES (1) | ES2901785T3 (en) |
| FI (1) | FI3977993T3 (en) |
| HR (1) | HRP20211834T1 (en) |
| HU (1) | HUE056583T2 (en) |
| IL (1) | IL251037A0 (en) |
| LT (1) | LT3191461T (en) |
| MX (1) | MX2017002954A (en) |
| NZ (1) | NZ766084A (en) |
| PL (1) | PL3191461T3 (en) |
| PT (1) | PT3191461T (en) |
| RS (1) | RS62634B1 (en) |
| SG (1) | SG11201700958YA (en) |
| SI (1) | SI3191461T1 (en) |
| TW (1) | TWI644902B (en) |
| WO (1) | WO2016038500A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571950A (en) * | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
| EP3953339A1 (en) * | 2019-04-11 | 2022-02-16 | Inke, S.A. | Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate |
| KR20220017932A (en) * | 2019-05-16 | 2022-02-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | Solid form of tapamidis and its salts |
| WO2021001858A1 (en) * | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| EP4059926A4 (en) | 2019-11-15 | 2022-12-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of tafamidis and preparation method therefor and use thereof |
| IL294115A (en) * | 2019-12-20 | 2022-08-01 | Pfizer Ireland Pharmaceuticals | Efficient process for making 6-carboxy benzoxazole derivatives |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| WO2021232619A1 (en) * | 2020-05-19 | 2021-11-25 | 苏州科睿思制药有限公司 | Crystal form of tafamidis free acid, preparation method therefor and use thereof |
| WO2022009221A1 (en) * | 2020-07-04 | 2022-01-13 | Nuray Chemicals Private Limited | Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
| WO2022107166A1 (en) * | 2020-11-20 | 2022-05-27 | Natco Pharma Limited | Novel crystalline form of tafamidis and its process thereof |
| WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
| CN114907283A (en) * | 2021-02-07 | 2022-08-16 | 南京正大天晴制药有限公司 | Preparation method of 2- (3, 5-dichlorophenyl) -benzoxazole-6-carboxylic acid |
| EP4083027A1 (en) | 2021-04-26 | 2022-11-02 | Química Sintética, S.A. | A solid state form of tafamidis and a process for its preparation |
| WO2023020762A1 (en) | 2021-08-16 | 2023-02-23 | Synthon B.V. | Crystalline forms of tafamidis nicotinamide adduct |
| WO2023091534A1 (en) | 2021-11-17 | 2023-05-25 | Teva Pharmaceuticals International Gmbh | Solid state form of tafamidis |
| WO2024023710A1 (en) | 2022-07-28 | 2024-02-01 | Pfizer Inc. | Tafamidis pharmaceutical compositions |
| US11878081B1 (en) | 2022-12-23 | 2024-01-23 | Tap Pharmaceuticals Ag | Pharmaceutical formulations of tafamidis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CN101413143B (en) * | 2002-12-19 | 2013-09-18 | 斯克里普斯研究学院 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| AU2007330478B2 (en) * | 2006-12-06 | 2011-09-08 | Conatus Pharmaceuticals, Inc. | Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| SG2014013270A (en) * | 2011-09-16 | 2014-05-29 | Pfizer | Solid forms of a transthyretin dissociation inhibitor |
| WO2013168014A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| KR20220017932A (en) | 2019-05-16 | 2022-02-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | Solid form of tapamidis and its salts |
| WO2021001858A1 (en) | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021152623A1 (en) | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
-
2015
- 2015-08-31 EP EP15771276.1A patent/EP3191461B1/en active Active
- 2015-08-31 NZ NZ766084A patent/NZ766084A/en unknown
- 2015-08-31 EP EP21203965.5A patent/EP3977993B1/en active Active
- 2015-08-31 ES ES15771276T patent/ES2901785T3/en active Active
- 2015-08-31 CN CN202211071641.7A patent/CN115368313A/en active Pending
- 2015-08-31 HU HUE15771276A patent/HUE056583T2/en unknown
- 2015-08-31 HR HRP20211834TT patent/HRP20211834T1/en unknown
- 2015-08-31 RS RS20211481A patent/RS62634B1/en unknown
- 2015-08-31 AU AU2015313875A patent/AU2015313875B2/en active Active
- 2015-08-31 SG SG11201700958YA patent/SG11201700958YA/en unknown
- 2015-08-31 FI FIEP21203965.5T patent/FI3977993T3/en active
- 2015-08-31 CN CN201580048168.2A patent/CN106715405A/en active Pending
- 2015-08-31 SI SI201531753T patent/SI3191461T1/en unknown
- 2015-08-31 MX MX2017002954A patent/MX2017002954A/en active IP Right Grant
- 2015-08-31 WO PCT/IB2015/056597 patent/WO2016038500A1/en active Application Filing
- 2015-08-31 KR KR1020177006011A patent/KR102004059B1/en active IP Right Grant
- 2015-08-31 DK DK21203965.5T patent/DK3977993T3/en active
- 2015-08-31 US US15/509,343 patent/US9770441B1/en active Active
- 2015-08-31 PL PL15771276T patent/PL3191461T3/en unknown
- 2015-08-31 EP EP24152053.5A patent/EP4349406A2/en active Pending
- 2015-08-31 PT PT157712761T patent/PT3191461T/en unknown
- 2015-08-31 BR BR112017003421-2A patent/BR112017003421B1/en active IP Right Grant
- 2015-08-31 LT LTEPPCT/IB2015/056597T patent/LT3191461T/en unknown
- 2015-09-02 JP JP2015172636A patent/JP2016065042A/en not_active Withdrawn
- 2015-09-03 CA CA2903194A patent/CA2903194A1/en not_active Abandoned
- 2015-09-07 TW TW104129562A patent/TWI644902B/en active
-
2017
- 2017-03-08 IL IL251037A patent/IL251037A0/en unknown
-
2019
- 2019-12-02 JP JP2019218244A patent/JP7357525B2/en active Active
-
2021
- 2021-11-09 JP JP2021182622A patent/JP2022024014A/en not_active Withdrawn
- 2021-12-16 CY CY20211101109T patent/CY1124843T1/en unknown
-
2023
- 2023-07-13 JP JP2023115087A patent/JP2023134645A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251037A0 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | |
| IL268799A (en) | Modified cyclic dinucleotide compounds | |
| GB201417002D0 (en) | Novel compound | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| IL246385B (en) | Crystalline forms of afatinib di-maleate | |
| IL250038A0 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| SI3380554T1 (en) | Crystalline forms of per-chloro-gamma-cyclodextrines | |
| HK1244274A1 (en) | Crystalline forms of c21h22ci2n4o2 | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| PT3113773T (en) | Crystalline forms of grapiprant | |
| IL253479A0 (en) | Crystalline forms of efinaconazole | |
| IL265445A (en) | Crystalline forms | |
| HK1221463A1 (en) | Novel compounds useful as s100-inhibitors s100 | |
| GB201419174D0 (en) | Crystalline forms | |
| PL3159335T3 (en) | Novel heterocyclic compound | |
| GB201407506D0 (en) | Novel compound | |
| EP3177280A4 (en) | Synthesis of 2,2,2-trifluoroethanethiol | |
| ZA201902553B (en) | Crystalline forms | |
| ZA201701284B (en) | Carbondisulfide derived zwitterions | |
| SG10201402964RA (en) | Dehydration of 2,3-butanediole | |
| GB201416988D0 (en) | Novel compound | |
| GB201408238D0 (en) | Synthesis of substituted 1,2,3-Triazoles |